• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

BK060027 Letter

August 1, 2006

CytoTherm LP
Attn: Roman Kuzyk
110 Sewell Avenue
Trenton, NJ 08610

 

Re: BK060027
Product: CytoTherm Plasma Thawing System
Date Received: 10-MAY-06
Classification: II
Device Code: KZL

Dear Mr. Kuzyk:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 835-4709 or (301) 827-1800 or at its Internet address: http://www.fda.gov/cber/smlbus.htm.

Sincerely yours,

Alan E. Williams, Ph.D.
Director
Division of Blood Applications
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Enclosure


 

Indications for Use

510(k) Number: BK060027

Device Name: CytoTherm Plasma Thawing Systems
                            Models CT-4T, CT-DR, CT-D4, CT-D2

Indications For Use:

Class II, 81KZL Device

Tabletop frozen plasma thawing system. Used to thaw frozen plasma in hospitals or lab blood bank settings, including trauma centers. Wet and dry thawing, small and large volume.

Wet thawing units - ports are protected above the water level. Ability to thaw up to 12 units of 450 mL frozen plasma bags. Dry thawing units - easy to load, leak detection sensors, filtered air.

Units tested with full load of 300 mL bags with 250 mL plasma, frozen for 48 hours at -22 deg C. ETL tested (#65452), UL Std. 2601-1, CAN/CSA C22.2 No. 601.1